The objective of this workshop was to provide recommendations on several issues involving pallidotomy for patients with medically intractable Parkinson disease to physicians, patients, and other health care providers. An international consortium of experts in neurology, neurosurgery, and neurophysiology who had extensive experience with pallidotomy were invited to the workshop. Participants were sent background materials from the scientific literature for review-based participant recommendations. A proposed agenda was circulated to all participants before the workshop, and the final agenda was based on their recommendations. Topics were introduced at the workshop by members of the organizing committee, followed by extensive group discussion. A draft of a consensus statement, based on the previous day's discussion, was circulated and further modifications were made. The final statement was agreed on by all members.The conclusions of the participants were: (1) Pallidotomy should be performed only at centers that have a team of physicians with substantial expertise and experience in the field. (2) Patients with disabling idiopathic Parkinson disease, without dementia, and who have exhausted medical therapy should be considered for pallidotomy. (3) All patients should be examined by means of standardized rating scales both preoperatively and postoperatively to ensure quality of care at each center. (4) Symptoms that respond best to pallidotomy include medication-induced dyskinesias, rigidity, and tremor, while balance, gait disorders, and hypophonia are generally less responsive to surgery. Benefits of pallidotomy appear to be long lasting. (5) Each institution's complication rate should be discussed before surgery.
Surgical operations in the basal ganglia for idiopathic Parkinson disease (PD) were described as early as 1940.1Surgical approaches have concentrated on ablation of small regions of the basal ganglia and thalamus, implantation of dopamine-secreting cells, and deep-brain electrical stimulation. In early studies, stereotactic lesions in the globus pallidus appeared to improve rigidity, but inconsistent results were reported for the relief of tremor and bradykinesia.2,3 Even though Svennilson et al3reported consistent benefit for tremor, rigidity, and bradykinesia with a more posterior, ventral, and lateral target, many neurosurgeons moved to the thalamus because of unpredictable outcomes with pallidotomy. Thalamotomy was found to result in long-lasting improvement in tremor and rigidity but not bradykinesia.4 Surgical approaches for the treatment of PD became less frequent when levodopa therapy became available in the late 1960s. Despite advances in the medical management of PD, however, patients often develop severe disabling medication-induced dyskinesias and motor fluctuations. These persistent problems led to further investigations of a role for stereotactic surgery in the treatment of PD and other movement disorders.5
Several centers around the world have applied magnetic resonance (MR) imaging, electrophysiological testing, and modern stereotactic neurosurgical techniques to improve the outcome of ablative therapy and reduce the rate of complications. The efficacy of stereotactic pallidotomy in treating patients with medically intractable PD is supported by several recent reports (Table 1).6-21 None of these studies was double-blinded or placebo controlled, they had a small population size, and there were potential management biases; therefore, definitive conclusions regarding indications, extent of improvement, and complications cannot be drawn. Recently, a preliminary report of a randomized study has been presented, and results from this study also support the efficacy of the procedure.18The ethics and costs of sham surgery make blinded trials extremely difficult. Although more than 390 pallidotomies are represented in the literature, many more operations have been performed but not formally reported. Therefore, a workshop was conducted to bring together many of the leading neurologists and neurosurgeons in the field to address many issues involving the procedure that remain unresolved. A consensus was reached on recommendations for patient selection, institutional requirements, preoperative and postoperative evaluation, lesion targeting, and anticipated benefits of the procedure. Below are the recommendations agreed on at this workshop.
Early surgical targets in treating patients with PD were discovered serendipitously. The current model of basal ganglia circuitry and dysfunction in disease at least partially predicts the therapeutic effects of pallidotomy.22,23In general, increased inhibitory output from the internal segment of the globus pallidus (GPi) is associated with parkinsonism, whereas decreased output is associated with dyskinesias. Loss of striatal dopamine in the case of PD leads to overactivity of the indirect pathway (excitatory) and underactivity of the direct pathway (inhibitory) to the GPi. This ultimately leads to excessive inhibition of the thalamus by the GPi. Lesions of the posteroventral aspects of the pallidum presumably interfere with the excessive pallidal inhibition of the thalamus and brainstem. This simple model does not predict, however, the dramatic effect pallidotomy has on drug-induced dyskinesias. This and other shortcomings of the current models have been discussed in several recent reviews.
Participants of the panel were invited on the basis of their expertise in the area of pallidotomy and basal ganglia function. Ninety percent of those invited attended the workshop or sent a representative from their institution. Their expertise was based on having at least 1 peer-reviewed publication in the field and/or practice at centers that perform a high volume of procedures. Approximately an equal number of neurologists and neurosurgeons were invited.
All opinions in this statement represent those who attended the workshop (13 neurologists, 12 neurosurgeons, and 3 basic scientists).
We distributed a proposed agenda and several reprints to all participants before the meeting. Participants were encouraged to suggest changes to the agenda and additional articles. These additional materials were then distributed in a second mailing.
On arrival, all participants received a packet containing the final agenda and names of all participants. Topics were introduced by one of us (J.M.B, A.D., or M.R.D.), and experts in that topic were asked to present their views. Discussion was then opened to the floor, allowing all participants to contribute. Detailed notes of the discussions were taken by 2 individuals, and the entire meeting was tape recorded. Before the end of the meeting, a preliminary statement was prepared and distributed on the last day. Each issue was discussed again. The final statement was prepared by us on the basis of this final discussion, and the manuscript was sent to all participants for their final comments and approval.
Recommended institutional requirements
Stereotactic pallidotomy should be performed at centers with a team of physicians and support staff. All patients should be examined and medically treated by a neurologist with expertise in diagnosing and caring for patients with PD. It is recommended that the neurosurgeon be trained in stereotactic and functional neurosurgery and the institution be well equipped. Adequate facilities should provide high-resolution MR imaging (with appropriate software) and full stereotactic capabilities. As with many surgical procedures, experience is important in obtaining optimal outcomes. It is therefore recommended that a pallidotomy center perform at least 25 procedures per year and have an established track record.
There was consensus in the panel that the following criteria be used to select patients for pallidotomy.
Patients with idiopathic PD who have exhausted medical therapy to control disabling symptoms should be considered as possible candidates for pallidotomy. The criteria for the diagnosis of PD requires (1) the presence of at least 2 of the cardinal features of PD (rest tremor, rigidity, and bradykinesia); (2) clear response to levodopa (patients should be examined in both the "on" and "off" states); (3) no evidence of other causes (encephalitis, exposure to toxins, recent exposure to neuroleptics, head trauma, or relevant vascular disease); (4) lack of cerebellar ataxia, vertical gaze palsy, and pronounced autonomic features; and (5) MR images without lacunar infarcts that are thought to be causative of the parkinsonism, normal-pressure hydrocephalus, and marked cerebellar and/or brainstem atrophy.
An appropriate surgical candidate should have persistent disability despite optimal medical management. The degree of disability depends on the individual and the nature of the disability. It was the general opinion at the workshop that no maximum or minimum age or stage of the disease should preclude consideration for pallidotomy. This opinion was based on the fact that effective pallidotomies have been safely performed on patients from 30 to 82 years of age, although some participants suggested that younger patients obtain better results from pallidotomy than older patients. Because several disorders can easily be mistaken for PD and the management of advanced PD can be difficult, the panel believed that patient evaluations and treatment should be performed by a neurologist with expertise in movement disorders.
Patients with Parkinson-plus syndromes (multiple-system atrophy, progressive supranuclear palsy, vascular parkinsonism, etc) should not be considered for pallidotomy, since it has been found to be ineffective in these disorders. Patients with dementia should not be considered for pallidotomy because the cognitive status of the patient may worsen as a result of the procedure (see "Cognitive Screening" section, below). Patients with medical conditions that add unacceptable surgical risk or have MR imaging evidence of other intracranial disease are poor candidates for this procedure. Substantial psychiatric disorders, including severe depression and psychosis, should exclude patients from pallidotomy, although patients with depression can be treated and then considered for surgery.
Preoperative and postoperative evaluations
Standardized outcome analysis is extremely important in ensuring quality of care at each center, especially as they are becoming established. The participants believed that all patients should be examined in the on and off states both preoperatively and postoperatively by means of the United Parkinson's Disease Rating Scale,24the Hoehn and Yahr Staging Scale,25and the Schwab and England activities of daily living scale.26It is also recommended that a measure of quality of life be used, although no one scale has yet been universally accepted.27,28The Parkinson's Disease Study Group is developing a quality-of-life rating system for patients with PD (the PDQUALW), and the panel believed that it should also be considered when available. Positron emission tomography may have some usefulness in predicting outcomes in some patients,29but the participants thought that further investigation is necessary before its use can be endorsed.
The cognitive status of patients with PD does not appear to change markedly after pallidotomy if there are no major preexisting cognitive deficits,11,12,16,30although this is not firmly established. Since patients with dementia may worsen after pallidotomy, the panel believed that it is imperative to perform an adequate preoperative cognitive evaluation on all patients. In general, patients who fulfill criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,31 for dementia or have a substantial isolated amnestic syndrome should be excluded. Formal neuropsychological testing may not be necessary for all patients. Masterman et al12,30found a 4-part cognitive battery adequate as a first screening tool to identify those who should undergo more formalized testing. This battery includes a Mini-Mental State Examination,32memory problem checklist, Superspan Memory Test,33and a behavioral assessment (ie, Neuropsychiatric Inventory,34Beck Depression Inventory,35or Hamilton Depression Scale36). Verification of this or other preoperative cognitive evaluation is required before any one evaluation could be endorsed by the panel.
Several issues should be discussed with all patients before surgery. It should be made clear that pallidotomy treats some symptoms better than others and that patients should have realistic expectations. In general, levodopa-induced dyskinesias and dystonias (especially "on-time" painful dystonias) and motor fluctuations are highly responsive to pallidotomy in the majority of patients. Rigidity, bradykinesia or akinesia, tremor, and facial masking are also clearly responsive to surgery. Less and more variably responsive symptoms include gait disorders (festinating gait, turning, and step size), posture, balance, hypophonia, micrographia, and "off-time" freezing. Nonresponsive symptoms include autonomic dysfunction, sphincteric signs (ie, incontinence), drooling and swallowing difficulties, and cognitive impairment. On-period disability that is unrelated to dyskinesias rarely improves in response to pallidotomy. Benefits from surgery appear to be long lasting,15 with 1 report demonstrating improvements up to 4 years.37 Detailed studies on larger series are necessary to fully define long-term results of pallidotomy.
In general, surgical complications from pallidotomy are infrequent, but substantial morbidity and mortality have been reported (Table 1). In the published literature, 3.6% (15/416) of all patients sustained a permanent visual field defect, 1.4% (6/416) sustained a permanent hemiparesis, and several patients had transient symptoms.38 In 1 report, 3 delayed internal capsule infarcts occurred 13 to 117 days after pallidotomy, all in patients with known vascular risks.39 Three deaths have been reported in the modern literature,17,19 2 of them occurring in their early cases. In fact, most centers reported that the majority of their complications occurred early in their series, and the rate fell with experience. For this reason, the panel recommends that centers have a considerable amount of experience in performing pallidotomies (see recommended institutional requirements) and that patients discuss with their physician the complication rate for each center. Potential surgical patients should also understand that they may be excluded from future medical and surgical trials and that pallidotomy may alter the effectiveness of future therapies.
There are much fewer data available evaluating the benefits and complications of bilateral pallidotomy.9,40,41 There have been a few reports of speech and swallowing difficulties after bilateral pallidotomy, but there is little evidence that bilateral surgery poses additional cognitive risks after well-placed lesions are administered. Many of the participants at the workshop have successfully performed staged bilateral pallidotomies with good results, although some complications have occurred. It is unclear whether these complications reflect poorly placed lesions or the risk of adverse events is inherently greater when a second procedure is performed (ie, more than twice the risk of unilateral pallidotomy). Since unilateral pallidotomy often has bilateral benefits and bilateral surgery may pose additional risks, the panel believed that bilateral pallidotomy should be considered only as a staged procedure with at least a 6-month interval between surgeries. Indications for a second pallidotomy include severe drug-induced symptoms on the side not operated on and a good response to the previous surgery. Patients with speech or swallowing difficulties (by history and examination) or cognitive decline after the first procedure should be excluded from a second operation.
Before surgery, all antiplatelet agents (aspirin, noncorticosteroidal anti-inflammatory agents, etc) should be discontinued for at least 2 weeks. The blood pressure should be well controlled preoperatively, postoperatively, and intraoperatively to avoid intracerebral hemorrhage. Antiparkinson medications should be limited the day of surgery to achieve a modest off state but avoid dangerous and uncomfortable severe rigidity, akinesia, and off dystonia.
There is some variation between centers as to where lesions are targeted. Benefits from surgery have been shown to result in both patients and animal models from lesions confined to the caudal (sensorimotor) portion of the globus pallidus pars interna (GPi). Lesions directed to the posteroventral pallidum that include both GPi and external segment of the globus pallidus (GPe) have been reported to be effective in patients.6,13 Further studies are necessary to better define ideal lesion placement.
The techniques used to determine the target coordinates varied at different centers, but most used MR imaging–guided stereotaxis. Computed tomography–guided targeting has also been reported to be relatively safe and effective.19Since both MR imaging– and computed tomography–determined targets can be inaccurate and since the target cannot be adequately determined on anatomical grounds alone, there is general agreement on the need for electrophysiological guidance (stimulation) and intraoperative examination. For this reason, it is strongly recommended that radiosurgery (eg, gamma knife) not be used to perform pallidotomy. Consensus regarding the added value of microelectrode mapping was not reached because of a lack of data. Safe and effective pallidotomies have been performed both with and without microelectrode recordings (Table 1). The panel believed that there is no evidence that microelectrode mapping is associated with additional surgical complications (eg, hemorrhage, infection). Microelectrode mapping requires both special equipment and experienced personnel and should be performed only at centers with expertise in this technique.
Many centers perform postoperative MR imaging or computed tomography to determine if a hemorrhage has occurred. It was generally agreed that these images offer little in determining lesion placement at conventional resolution.
In our deliberations, we reached consensus on several issues involving pallidotomy. It is recommended that pallidotomy be performed at centers that have a team of experts to ensure that patients are adequately examined and medically treated before surgery is considered. Neurosurgeons should be trained in stereotactic and functional surgery, be well equipped, and have an established track record. Only patients with idiopathic PD and persistent disability who have exhausted medical therapy should be considered for pallidotomy. Good candidates should not have dementia or other medical conditions that would add substantial surgical risk. Standardized rating scales are recommended to ensure quality of care at each center. Several issues should be discussed with all patients before surgery so they will have realistic expectations of potential benefits and surgical risks. It was generally agreed that contralateral medication-induced dyskinesias, rigidity, and tremor are the most responsive symptoms, while gait disorders, hypophonia, balance, and freezing are less or more variably responsive symptoms. Nonresponsive symptoms include autonomic dysfunction, incontinence, drooling and swallowing difficulties, and cognitive impairment. Surgical complications are generally few, but the complication rate at each center should be discussed. There was less agreement on bilateral pallidotomy, since much less information is available, but it may pose an increased risk of speech and swallowing difficulties. It was agreed that if bilateral procedures were to be performed, they should be staged. Consensus was reached on the general region where the lesion should be placed (posteroventral pallidum including the GPi), but the panel believed that insufficient data were available to make more specific recommendations.
Accepted for publication August 31, 1998.
This study was supported by educational grants from Pharmacia and UpJohn Inc, Kalamazoo, Mich, DuPont Merck Pharmaceutical, Wilmington, Del, Athena Neurosciences, South San Francisco, Calif, Elekta Instruments, Atlanta, Ga, Parke-Davis, Morris Plains NJ, Radionics Instruments, Burlington, Mass, the University of California, Los Angeles, Brain Research Institute, and National Parkinson's Disease Foundation, Miami, Fla.
We thank Henrietta Salazar for her assistance in organizing the workshop.
New York University School of Medicine, New York, NY:Ron Alterman, MD; Aleksandar Beric, MD. Barrow Neurological Institute, Phoenix, Ariz:Konstantin Baev, MD, PhD; Abraham Lieberman, MD, Andrew Shetter, MD. Université Joseph Fourier de Grenoble, Grenoble, France:Alim Benabid, MD, PhD. University of California, Los Angeles, School of Medicine, Los Angeles:Jeff Bronstein, MD, PhD; Marie-Françoise Chesselet, MD, PhD; Jeffery Cummings, MD; Antonio DeSalles, MD, PhD; Robert Frysinger, PhD; Donna Masterman, MD; Alan Tobin, PhD. Massachusetts General Hospital, Boston:G. Rees Cosgrove, MD, FRCS. Emory University School of Medicine, Atlanta, Ga:Mahlon DeLong, MD; Jerrold Vitek, MD, PhD. University of Southern California School of Medicine, Los Angeles:Michael Dogali, MD; Cheryl Waters, MD. Conemaugh Memorial Medical Center, Johnstown, Pa: Karl Green, MD. University Hospital, Umea, Sweden: Marwan Hariz. Good Samaritan Hospital, Los Angeles: Dean B. Jacques, MD; Oleg Kopyov, MD, PhD. Sophiahemmet Hospital, Stockholm, Sweden:Lauri V. Laitinen, MD, PhD. Toronto Western Hospital, Toronto, Ontario:Anthony Lang, MD; Andre Lozano, MD, PhD. University of Kansas Medical Center, Kansas City:Edison Miyawaki, MD. University of London Queen Square, London, England:Niall Quinn, MD. Mayo Clinic Jacksonville, Jacksonville, Fla:Ryan J. Uitti, MD; Robert E. Wharen, Jr, MD.
Reprints: J. M. Bronstein, MD, PhD, University of California, Los Angeles, School of Medicine, Department of Neurology, Reed Neurological Research Center, 710 Westwood Plaza, Los Angeles, CA 90024 (e-mail: jbronste@ucla.edu).
1.Myers
HR Surgical procedure for postencephalitic tremor, with notes on the physiology of premotor fibers.
Arch Neurol Psychiatry. 1940;44445- 459
Google Scholar 3.Svennilson
ETorvik
ALowe
RLesksell
L Treatment of parkinsonism by stereotactic thermolesions in the pallidal region.
Acta Psychiatr Neurol Scand. 1960;35358- 377
Google ScholarCrossref 4.Hassler
RRiechert
T Indikationen und Lokalisations-methode der gezielten Hirnoperationen.
Nervenarzt. 1954;25441- 447
Google Scholar 5.Laitinen
LVBergenheim
ATHariz
MI Ventroposterolateral pallidotomy can abolish all parkinsonian symptoms.
Stereotact Funct Neurosurg. 1992;5814- 21
Google ScholarCrossref 6.Laitinen
LVBergenheim
ATHariz
MI Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease [see comments].
J Neurosurg. 1992;7653- 61
Google ScholarCrossref 7.Lozano
AMLang
AEGalvez-Jimenez
N
et al. Effect of GPi pallidotomy on motor function in Parkinson's disease.
Lancet. 1995;3461383- 1387
Google ScholarCrossref 8.Dogali
MFazzini
EKolodny
E
et al. Stereotactic ventral pallidotomy for Parkinson's disease.
Neurology. 1995;45753- 761
Google ScholarCrossref 9.Iacono
RPShima
FLonser
RRKuniyoshi
SMaeda
GYamada
S The results, indications, and physiology of posteroventral pallidotomy for patients with Parkinson's disease [see comments].
Neurosurgery. 1995;361118- 1127
Google ScholarCrossref 10.Sutton
JPCouldwell
WLew
MF
et al. Ventroposterior medial pallidotomy in patients with advanced Parkinson's disease [see comments].
Neurosurgery. 1995;361112- 1117
Google ScholarCrossref 11.Baron
MSVitek
JLBakay
RA
et al. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study [see comments].
Ann Neurol. 1996;40355- 366
Google ScholarCrossref 12.Masterman
DLDeSalles
ABaloh
RW
et al. Motor, cognitive, and behavioral performance following unilateral ventroposterior pallidotomy for Parkinson disease.
Arch Neurol. 1998;551201- 1208
Google ScholarCrossref 13.Johansson
FMalm
JNordh
EHariz
M Usefulness of pallidotomy in advanced Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1997;62125- 132
Google ScholarCrossref 14.Krauss
JKDesaloms
JMLai
ECKing
DEJankovic
JGrossman
RG Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis.
J Neurosurg. 1997;87358- 367
Google ScholarCrossref 15.Lang
AELozano
AMMontgomery
EDuff
JTasker
RHutchinson
W Posteroventral medial pallidotomy in advanced Parkinson's disease.
N Engl J Med. 1997;3371036- 1042
Google ScholarCrossref 16.Uitti
RJWharen
RETurk
MF
et al. Unilateral pallidotomy for Parkinson's disease: comparison of outcome in younger versus elderly patients.
Neurology. 1997;491072- 1077
Google ScholarCrossref 17.Samuel
MCaputo
EBrooks
DJ
et al. A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications.
Brain. 1998;12159- 75
Google ScholarCrossref 18.Vitec
JLBakay
RAEFreeman
A
et al. Randomized trial of pallidotomy for Parkinson's disease [abstract].
Neurology. 1998;50
(suppl 4)
A80Abstract S10.006.
Google Scholar 19.Kishore
ATurnbull
IMSnow
BJ
et al. Efficacy, stability and predictors of outcome of pallidotomy for Parkinson's disease: six-month follow-up with additional 1-year observations.
Brain. 1997;120729- 737
Google ScholarCrossref 20.Alterman
RLKelly
PJ Pallidotomy technique and results: the New York University experience.
Neurosurg Clin N Am. 1998;9337- 343
Google Scholar 21.Shannon
KMPenn
RDKroin
JS
et al. Stereotactic pallidotomy for the treatment of Parkinson's disease: efficacy and adverse effects at 6 months in 26 patients.
Neurology. 1998;50434- 438
Google ScholarCrossref 22.Albin
RLYoung
ABPenney
JB The functional anatomy of basal ganglia disorders [see comments].
Trends Neurosci. 1989;12366- 375
Google ScholarCrossref 23.Alexander
GEDeLong
MRStrick
PL Parallel organization of functionally segregated circuits linking basal ganglia and cortex.
Annu Rev Neurosci. 1986;9357- 381
Google ScholarCrossref 24.Fahn
SElton
RLMembers of the United Parkinson's Disease Rating Scale Development Committee, In: Fahn S, Marsden CD, Goldstein M, Caine CD, eds. Recent Developments in Parkinson's Disease, Volume II. Florham Park, NJ Macmillan Publishing Co Inc1987;153- 163
26.Schwab
RSEngland
AC Projection technique for evaluating surgery in Parkinson's disease. Gillingham
FJDonalson
IML
Third Symposium on Parkinson's Disease. Edinburgh, Scotland Churchill Livingstone1969;152- 157
Google Scholar 27.de Bocr
AGWijker
WSpeelman
JDde Haes
JC Quality of life in patients with Parkinson's disease: development of a questionnaire.
J Neurol Neurosurg Psychiatry. 1996;6170- 74
Google ScholarCrossref 28.Jenkinson
CPeto
VFitzpatrick
RGreenhall
RHyman
N Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the short-form health survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39).
Age Ageing. 1995;24505- 509
Google ScholarCrossref 29.Eidelberg
DMoeller
JRIshikawa
T
et al. Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's disease.
Ann Neurol. 1996;39450- 459
Google ScholarCrossref 30.Masterman
DLBronstein
JMDeSalles
AFoti
DCummings
JL Cognitive and behavioral performance following unilateral ventroposterior pallidotomy [abstract].
Neurology. 1997;48
(suppl P04)
100
Google Scholar 31.American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC American Psychiatric Association1994;
32.Folstein
MFFolstein
SEMcHugh
PR "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician.
J Psychiatr Res. 1975;12189- 198
Google ScholarCrossref 33.McCarthy
MFerris
SHClark
ECrook
T Acquisition and retention of categorized material in normal aging and senile dementia.
Exp Aging Res. 1981;7127- 135
Google ScholarCrossref 34.Cummings
JLMega
MGray
KRosenberg-Thompson
SCarusi
DAGornbein
J The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.
Neurology. 1994;442308- 2314
Google ScholarCrossref 35.Beck
ATWard
CHMendelson
MMock
JErbaugh
JK An inventory for measuring depression.
Arch Gen Psychiatry. 1961;4561- 571
Google ScholarCrossref 37.Fazzini
EDogali
MSterio
DEidelberg
DBeric
A Stereotactic pallidotomy for Parkinson's disease: a long-term follow-up of unilateral pallidotomy.
Neurology. 1997;481273- 1277
Google ScholarCrossref 38.Hariz
MIDe Salles
AF The side effects and complications of posteroventral pallidotomy.
Acta Neurochir. 1997;68
(suppl)
42- 48
Google Scholar 39.Lim
JYDe Salles
AFBronstein
JMMasterman
DSaver
JL Delayed internal capsule infarcts following radiofrequency pallidotomy.
J Neurosurg. 1997;87955- 960
Google ScholarCrossref 40.Roberts
JWHeilbrun
MP Staged bilateral ventroposterolateral pallidotomy for Parkinson's disease. Paper presented at: 49th Annual Meeting of the American Academy of Neurology April 17, 1997 Boston, Mass.
41.Ghika
JFavre
JFankhauser
HRegli
F Neurological and neuropsychological complications of bilateral contemporaneous pallidotomy in Parkinson's disease. Paper presented at: 48th Annual Meeting of the American Academy of Neurology March 28, 1996 San Francisco, Calif.